Alector Inc. cuts its workforce by nearly 50% following the failure of its dementia drug trial, signalling challenges in the ...

A lector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like ...

Bay Area biopharmaceutical company Alector, Inc. is cutting dozens of jobs after the reported flop of its most recent drug trial. According to a Worker Adjustment Retraining ...

The firm's monoclonal antibody latozinemab did not slow disease progression in patients with dementia due to progranulin gene mutations.

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...

Alector stock has experienced a notable shift in analyst sentiment after recent program setbacks, as reflected in the consensus analyst price target dropping from $3.83 to $2.20 per share. This sharp ...

Takeda Pharmaceutical Co. Ltd. agreed to codevelop and commercialize up to three of Innovent Biologics Co. Ltd.’s immuno-oncology (I-O) and antibody-drug conjugate (ADC) candidates with the signing of ...

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

Alector Therapeutics is shelving a GSK-partnered antibody after the asset failed to slow disease progression in patients with ...

Arcturus Therapeutics reported interim results from a mid-stage study of an mRNA-based treatment for cystic fibrosis that ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...